The Acquired Immuno Deficiency Syndrome (AIDS) remains a major global public health challenge especially in Africa. The deadline set for the Millennium Development Goals (MDGs) has elapsed, meanwhile most low and middle income countries did not reach the targets. With regards to the fight against HIV / AIDS, many African countries show slow progress in implementing efficient and effective strategies to counter this pandemic. The fact that most HIV/AIDS programs in Sub-Saharan African countries are still very dependent on external funding to carry out their activities, including the supply of Antiretroviral Treatment (ART), highlights the concern of sustainability. So far, solutions that have been proposed are mainly symptomatic, claiming more budget commitment from government. Without rejecting this view, we call for the implementation of sustainable solutions to deal with the long term ART challenges. A way forward is to promote the establishment of an effective machinery for the manufacturing and large scale distribution of ART. In addition to the health gains, we argue that such an initiative would have a three-dimensional impact: (i) political, (ii) economic and (iii) social.
Opinion
The Acquired Immuno Deficiency Syndrome (AIDS) Brazil, an emerging country is a remarkable example with one of the highest ART coverage in the world [5] . The strategy developed and implemented by the Brazilian political and health authorities to achieve such an outcome should serve as a pathway and lead African countries, though the investment cost at the beginning of the implementation process may seem prohibitive. To produce such a transformational change, the country has developed its capacity to locally produce ART, with eleven drugs among the 20 currently available in the country being produced by public sector industries [6] . This strategy targeting universal coverage in ART despite demanding huge investment (investment cost) during the initiation phases, enables substantial benefits in a long run. Although some African countries like South Africa manufacture some of the ART molecules for local use, production capacity remains low and does not permit an optimum coverage of eligible persons living with HIV/AIDS (PLHIV) in the country [7] . African manufacturers depend on foreign inputs for the bulk of their production; practically all the machine, laboratory equipments and reagents, raw materials such Unfortunately, it is estimated that almost 95% of the continent's API needs are met by imports [8, 9] . Indeed, African Traditional Medicine and the continent's rich biodiversity represents a raw materials of choice, but over 80% of Africa's natural raw materials have not been subjected to standard scientific evaluation. This leads to a great number of countries of the continent largely relying on India and China for imports of raw materials [10, 11] . Evidence suggests that building up local production of medicines help display greater availability and accessibility [12] . Thus, it is worth, for the African continent which harbors the majority of HIV/AIDS cases to develop its regional capacity to manufacture ART and render them accessible and affordable, at a scale that favours competition with foreign pharmaceutical firms. This will not only improve the reliability and sustainability of drug supply chain, and therefore Page number not for citation purposes 3 benefits in terms of public health, but will also be a precursor of socio-economic and political benefits.
Health gains
Throughout the progress of HIV/AIDS infection physiopathology, outcome of AIDS is usually associated with poor adherence to treatment protocol which may be caused by a rupture in ART supply chain [13] . Hence, disease prognosis will depend on the availability, accessibility of ART and adherence of HIV/AIDS eligible patients to the therapeutic protocol. In set of opportunistic infections due to improper treatment requires additional medication, which implies extra financial burden for patients and their families, accentuating poverty and perpetuating the cycle "poverty -disease". So putting in place ART manufacturing plants, defining good drug distribution networks and strategies, coupled to close monitoring and follow-up of patient to ensure compliance to treatment will lead to direct significant reductions in morbidity and co-morbidities; by a decreased incidence of opportunistic diseases in these patients. In addition, tuberculosis which is the major cause of death among HIV/AIDS [13] would be greatly reduced leading to considerable reduction in mortality rates.
Political advantages of ART manufacturing plants
Politically, the manufacture of ART requires a real and strong cooperation between the countries involved for the transfer of skills, experience and technology. In a rapidly changing world, addressing 
Social and economic benefits
From an economic perspective, local production of ART at large scale is undoubtedly associated with huge profits. The construction and maintenance of heavy industries as well as the processes involved in drug manufacturing requires extensive man power. This To speed up the process towards meeting up with these targets, it is primordial that self-financing and self-sufficiency means be developed. This is a foundation to ensure sustainability in the availability of ART even when the mobilization of external funds becomes less effective or undergoes a significant reduction; usually accompanied with large-scale and long term adverse impacts.
However, emphasis should be laid on the fact that, the implementation of local production firms by African countries relies 
